[go: up one dir, main page]

DE60234824D1 - Induzierbares expressionssystem in eukaryotischen zellen - Google Patents

Induzierbares expressionssystem in eukaryotischen zellen

Info

Publication number
DE60234824D1
DE60234824D1 DE60234824T DE60234824T DE60234824D1 DE 60234824 D1 DE60234824 D1 DE 60234824D1 DE 60234824 T DE60234824 T DE 60234824T DE 60234824 T DE60234824 T DE 60234824T DE 60234824 D1 DE60234824 D1 DE 60234824D1
Authority
DE
Germany
Prior art keywords
expression system
eukaryotic cells
switch
inducible expression
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234824T
Other languages
English (en)
Inventor
Bernard Massie
Alaka Mullick
Peter C K Lau
Yasuo Konishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Application granted granted Critical
Publication of DE60234824D1 publication Critical patent/DE60234824D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60234824T 2001-05-01 2002-05-01 Induzierbares expressionssystem in eukaryotischen zellen Expired - Lifetime DE60234824D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28741801P 2001-05-01 2001-05-01
PCT/CA2002/000654 WO2002088346A2 (en) 2001-05-01 2002-05-01 A system for inducible expression in eukaryotic cells

Publications (1)

Publication Number Publication Date
DE60234824D1 true DE60234824D1 (de) 2010-02-04

Family

ID=23102808

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234824T Expired - Lifetime DE60234824D1 (de) 2001-05-01 2002-05-01 Induzierbares expressionssystem in eukaryotischen zellen

Country Status (7)

Country Link
US (2) US7745592B2 (de)
EP (1) EP1385946B1 (de)
AT (1) ATE452972T1 (de)
AU (1) AU2002257420A1 (de)
CA (1) CA2446110C (de)
DE (1) DE60234824D1 (de)
WO (1) WO2002088346A2 (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935788B2 (en) * 2004-10-04 2011-05-03 National Research Council Of Canada Reverse cumate repressor mutant
CA2580515C (en) 2004-10-04 2017-05-02 National Research Council Of Canada Expression system, components thereof and methods of use
WO2007022623A1 (en) * 2005-08-23 2007-03-01 National Research Council Of Canada Regulation of heterologous recombinant protein expression in methylotrophic and methanotrophic bacteria
US20080044855A1 (en) * 2006-03-22 2008-02-21 Yan Xu System for regulated and enhanced baculovirus mediated transient transgene expression in mammalian cells
EP2254998B1 (de) 2008-02-28 2015-12-23 Argos Therapeutics, Inc. Transiente expression immunmodulatorischer polypeptide zur vorbeugung und behandlung von autoimmunkrankheit, allergie und transplantatabstossung
JP6182456B2 (ja) 2010-12-22 2017-08-23 フェイト セラピューティクス，インコーポレイテッド 単細胞選別のための細胞培養プラットホームおよびｉＰＳＣの再プログラミングの増強
WO2012104843A1 (en) 2011-02-06 2012-08-09 Yeda Research And Development Co.Ltd. At The Weizmann Institute Of Science Affinity maturated t cell receptors and use thereof
EP2717922B1 (de) 2011-06-10 2018-09-12 Bluebird Bio, Inc. Gentherapievektoren für adrenoleukodystrophie und adrenomyeloneuropathie
UA114796C2 (uk) 2011-09-30 2017-08-10 Блубьод Байо, Інк. Спосіб підвищення ефективності трансдукції
EP3808844A1 (de) 2012-07-25 2021-04-21 The Broad Institute, Inc. Induzierbare dns-bindende proteine und genomperturbationswerkzeuge und deren anwendungen
CN104869987B (zh) 2012-09-07 2020-10-16 麻省眼耳医院 用于再生毛细胞和/或支持细胞的方法及组合物
US10548962B2 (en) 2012-10-22 2020-02-04 The Board Of Regents For Oklahoma State University Use of the salmonella SPP type III secretion proteins as a protective vaccination
US9950053B2 (en) 2012-10-22 2018-04-24 The Board Of Regents For Oklahoma State University Use of the Salmonella SPP type III secretion proteins as a protective vaccination
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
EP3831840A1 (de) 2013-03-15 2021-06-09 Celgene Corporation Modifizierte t-lymphozyten
WO2014194130A1 (en) * 2013-05-29 2014-12-04 Joule Unlimited Technologies, Inc. Methods and compositions for controlling gene expression in photosynthetic organisms
CN106414721A (zh) 2014-03-04 2017-02-15 菲特治疗公司 改良的重编程方法和细胞培养平台
US10590433B2 (en) 2014-03-14 2020-03-17 University Of Washington Genomic insulator elements and uses thereof
PT3689899T (pt) 2014-04-25 2021-11-30 2Seventy Bio Inc Recetores do antígeno quimérico do promotor mnd
KR20160141865A (ko) 2014-04-25 2016-12-09 블루버드 바이오, 인코포레이티드. 양자 세포 치료제를 제조하는 개선된 방법
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
CN111394317B (zh) 2014-06-06 2024-07-12 2赛文缇生物公司 改善的t细胞组合物
US20170137505A1 (en) 2014-06-20 2017-05-18 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
US20170137506A1 (en) 2014-06-20 2017-05-18 Aveo Pharmaceuticals, Inc. Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
CN106795217B (zh) 2014-07-24 2021-08-06 蓝鸟生物公司 Bcma嵌合抗原受体
PL3197493T3 (pl) 2014-09-25 2021-08-23 Aveo Pharmaceuticals Inc. Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego
EP3212773B1 (de) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Effiziente abgabe von therapeutischen molekülen an zellen des innenohres
SI3215187T1 (sl) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention B.V. Terapevtska cepiva HPV16
BR112017012502B1 (pt) 2014-12-12 2020-09-15 Bluebird Bio, Inc. Polinucleotídeo, polipeptídeo de car codificado pelo dito polinucleotídeo, vetor compreendendo o dito polinucleotídeo, composição compreendendo o dito vetor e método para geração de uma célula imune efetora compreendendo um car
EP3337500A1 (de) 2015-08-20 2018-06-27 Janssen Vaccines & Prevention B.V. Therapeutische hpv18-impfstoffe
CA2996893A1 (en) 2015-08-31 2017-03-09 Bluebird Bio, Inc. Anti-sialyl tn chimeric antigen receptors
CA3001917A1 (en) 2015-10-16 2017-04-20 Fate Therapeutics, Inc. Platform for the induction & maintenance of ground state pluripotency
EP3414321B8 (de) 2016-02-12 2023-05-03 bluebird bio, Inc. Vcn-förderer-zusammensetzungen und verfahren zur verwendung davon
US11326183B2 (en) 2016-02-12 2022-05-10 Bluebird Bio, Inc. VCN enhancer compositions and methods of using the same
EP4495248A3 (de) * 2016-04-12 2025-04-02 CarryGenes Bioengineering, LLC Verfahren zur erzeugung synthetischer chromosomen mit genregulatorischen systemen und verwendungen davon
EP3452087A1 (de) 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutische hpv-impfstoffkombinationen
BR112018072537A2 (pt) 2016-05-03 2019-03-26 Wayne State University método de reforço da liberação de um gene no olho através de mediação viral usando inibidores de proteassoma
EP3458485B1 (de) 2016-05-19 2021-12-29 The General Hospital Corporation An den rezeptor il-2rbeta gebundenes interleukin-2, eine plattform zur erhöhung der aktivität von natürlichen killer- und regulatorischen t-zellen
MA45996A (fr) 2016-08-16 2021-06-02 Bluebird Bio Inc Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
WO2018039333A1 (en) 2016-08-23 2018-03-01 Bluebird Bio, Inc. Tim3 homing endonuclease variants, compositions, and methods of use
EP3510157B1 (de) 2016-09-08 2023-05-31 2seventy bio, Inc. Pd-1-homing-endonukleasevarianten, zusammensetzungen und verfahren zur verwendung
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
KR102653324B1 (ko) 2016-11-17 2024-04-01 2세븐티 바이오, 인코포레이티드 TGFβ 신호 컨버터
EP4317447A3 (de) 2017-02-15 2024-05-01 2seventy bio, Inc. Multiplex-genomeditierung für spenderreparaturmatrizen
EP3615664A4 (de) 2017-04-24 2021-01-27 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Homologiegerichtete reparaturzusammensetzungen zur behandlung von hämoglobinopathien
SG11201911031TA (en) 2017-07-12 2020-01-30 Synlogic Operating Co Inc Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
KR20200055141A (ko) * 2017-10-10 2020-05-20 난트바이오 인코포레이티드 바이러스 생성 페이로드에 대해 독성이 낮은 변형된 ec7 세포(modified ec7 cells having low toxicity to viral production payloads)
WO2019140116A2 (en) 2018-01-10 2019-07-18 Rubius Therapeutics, Inc. Amplifiable rnas for therapeutic cell systems
GB201800903D0 (en) 2018-01-19 2018-03-07 Oxford Genetics Ltd Vectors
US20210207166A1 (en) * 2018-01-23 2021-07-08 Southern Eye Equipment Expression vector and method
EP3765094A4 (de) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. Genregulatorische zusammensetzungen und verfahren zur verbesserten immuntherapie
KR20200133219A (ko) 2018-03-15 2020-11-26 케이에스큐 세러퓨틱스 인코포레이티드 개선된 면역요법을 위한 유전자-조절 조성물 및 방법
US20190345261A1 (en) 2018-05-10 2019-11-14 Sensei Biotherapeutics, Inc. Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
BR112020023015A2 (pt) 2018-05-15 2021-02-17 Flagship Pioneering Innovations V, Inc. composições de fusossoma e usos das mesmas
IL312102A (en) 2018-06-14 2024-06-01 2Seventy Bio Inc CD79A chimeric antigen receptors
WO2020006409A1 (en) 2018-06-28 2020-01-02 Trustees Of Boston University Systems and methods for control of gene expression
KR20210043574A (ko) 2018-07-09 2021-04-21 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 푸소좀 조성물 및 이의 용도
EA202190243A1 (ru) 2018-07-11 2021-06-16 Селджин Корпорейшн Применение химерных антигенных рецепторов к bcma
CN113613633A (zh) 2018-11-14 2021-11-05 旗舰先锋创新V股份有限公司 用于cns递送的融合剂脂质体组合物
EP3880832A1 (de) 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Fusosomzusammensetzungen zur verabreichung von hämatopoetischen stammzellen
US20230043255A1 (en) 2018-11-14 2023-02-09 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
GB201901571D0 (en) * 2019-02-05 2019-03-27 Oxford Genetics Ltd Inducible AAV sysyem
EP3986922A2 (de) 2019-06-21 2022-04-27 Kite Pharma, Inc. Tgf-beta-rezeptoren und verwendungsverfahren
US12214218B2 (en) 2019-07-31 2025-02-04 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy
AU2020377930A1 (en) 2019-11-05 2022-05-19 Bristol-Myers Squibb Company Uses of anti-BCMA chimeric antigen receptors
GB202004371D0 (en) 2020-03-26 2020-05-13 Glaxosmithkline Ip Dev Ltd CAR constructs
CN113584083A (zh) 2020-04-30 2021-11-02 深圳市深研生物科技有限公司 用于逆转录病毒载体的生产细胞和包装细胞及其制备方法
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
CN113699147B (zh) * 2020-05-22 2023-06-09 深圳市深研生物科技有限公司 基于四环素和Cumate的共调控序列
CA3163572A1 (en) 2020-05-27 2021-12-02 Oleksandr PASTUKHOV Novel transduction enhancers and uses thereof
US11396646B2 (en) 2020-05-29 2022-07-26 QTG Development, Inc. Steviol glycosyltransferases and genes encoding the same
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
EP4501951A2 (de) 2020-08-25 2025-02-05 Kite Pharma, Inc. T-zellen mit verbesserter funktionalität
EP4217376A4 (de) * 2020-09-24 2024-10-09 University of Massachusetts Für nf1 codierende aav-vektoren und verwendungen davon
WO2022098685A2 (en) 2020-11-04 2022-05-12 Celgene Corporation Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
WO2022120160A1 (en) 2020-12-04 2022-06-09 Celgene Corporation Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
US11821014B2 (en) 2020-12-15 2023-11-21 Frito-Lay North America, Inc. Production of gentisic acid 5-O-β-D xylopyranoside
BR112023018987A2 (pt) 2021-03-19 2023-12-05 Glaxosmithkline Ip Dev Ltd Receptores de antígenos quiméricos direcionados à claudina-3 e métodos de tratamento do câncer
EP4314302A4 (de) 2021-03-24 2025-03-19 Dna Twopointo Inc Tetracyclininduzierbare expressionssysteme
AU2022257093A1 (en) 2021-04-16 2023-11-02 Celgene Corporation T cell therapy in patients who have had prior stem cell transplant
CA3225252A1 (en) 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies
CN118401659A (zh) 2021-10-14 2024-07-26 阿西莫夫公司 整合酶、着陆架架构和包括其的工程化细胞
EP4419685A1 (de) 2021-10-20 2024-08-28 University of Rochester Zusammensetzungen und verfahren zur behandlung von myelinmangel durch verjüngung glialer vorläuferzellen
EP4419654A1 (de) 2021-10-20 2024-08-28 University of Rochester Verfahren zur verjüngung glialer vorläuferzellen und regenerierte gliale vorläuferzellen per se
IL312487A (en) 2021-11-09 2024-07-01 Asimov Inc Stable production systems for aav vector production
WO2023150557A1 (en) 2022-02-01 2023-08-10 University Of Rochester Methods of generating a population of neurons from human glial progenitor cells and genetic constructs for carrying out such methods
EP4504249A2 (de) 2022-04-08 2025-02-12 Regeneron Pharmaceuticals, Inc. Multilaterale rezeptor- und signal-komplexe
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
IL317172A (en) 2022-05-26 2025-01-01 Regeneron Pharma Lentiviral vector maintenance vehicles and uses thereof
KR20250024051A (ko) 2022-06-09 2025-02-18 초 플러스 인크. 유전자 요법 (gene therapy) 벡터들 및 바이러스 백신들의 고 효율 생산을 위한 숙주 세포들로서의 세포 하이브리드들
WO2024042489A1 (en) 2022-08-25 2024-02-29 LifeEDIT Therapeutics, Inc. Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
WO2024064863A2 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
TW202417631A (zh) 2022-09-22 2024-05-01 美商拜奧馬林製藥公司 用ａａｖ基因治療載體治療心肌病
US20240165269A1 (en) 2022-10-19 2024-05-23 University Of Rochester Methods and compositions for rejuvenating cns glial populations with bcl11a transcription factor expression
WO2024127369A1 (en) 2022-12-16 2024-06-20 LifeEDIT Therapeutics, Inc. Guide rnas that target foxp3 gene and methods of use
WO2024127370A1 (en) 2022-12-16 2024-06-20 LifeEDIT Therapeutics, Inc. Guide rnas that target trac gene and methods of use
WO2024188356A1 (en) 2023-03-16 2024-09-19 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Ilt7-targeting antibodies and uses thereof
WO2024214071A1 (en) 2023-04-12 2024-10-17 LifeEDIT Therapeutics, Inc. Compositions and methods for the treatment of huntington's disease by editing the mutant huntingtin gene
WO2024243578A1 (en) 2023-05-25 2024-11-28 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025007073A2 (en) 2023-06-29 2025-01-02 Dispatch Biotherapeutics, Inc. Synthetic cytokine receptors
WO2025011529A2 (en) 2023-07-07 2025-01-16 Shanghai Circode Biomed Co., Ltd. Circular rna vaccines for seasonal flu and methods of uses
WO2025045142A1 (en) 2023-08-29 2025-03-06 Shanghai Circode Biomed Co., Ltd. Circular rna encoding vegf polypeptides, formulations, and methods of uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE123526T1 (de) 1987-08-17 1995-06-15 Hoffmann La Roche Hochreprimierbare expressionskontrollsequenzen.
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
US5589362A (en) 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
CA2165162C (en) * 1993-06-14 2000-05-23 Hermann Bujard Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch

Also Published As

Publication number Publication date
US20100210830A1 (en) 2010-08-19
CA2446110A1 (en) 2002-11-07
AU2002257420A1 (en) 2002-11-11
EP1385946A2 (de) 2004-02-04
WO2002088346A2 (en) 2002-11-07
US7745592B2 (en) 2010-06-29
US8163894B2 (en) 2012-04-24
EP1385946B1 (de) 2009-12-23
WO2002088346A3 (en) 2003-10-23
CA2446110C (en) 2013-06-25
US20040205834A1 (en) 2004-10-14
ATE452972T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
ATE452972T1 (de) Induzierbares expressionssystem in eukaryotischen zellen
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
ATE275628T1 (de) Expressionssteigernde sequenzelemente (ease) für eukaryontische expressionssysteme
BR9813608B1 (pt) célula hospedeira de bacillus transgênica, e, processo para produzir um polipeptìdeo tendo atividade aminopeptidase.
DK1017803T3 (da) Ekspression af endogene gener ved ikke-homolog rekombination af et vektorkonstrukt med cellulært DNA
CL2009002108A1 (es) Secuencia de adn que codifica una de secuencia aminoacidos con actividad farnesil pirofosfato sintetasa; vector que comprende dicha secuencia; celula huesped transformada con dicha secuencia; proceso de produccion de enzima para convertir isopentil pirofosfato a farnesil pirofosfato; y proceso para producir astaxantina (div. sol. no 891-99).
MXPA03007493A (es) Nuevo sistema de expresion genetica inducible a base de receptor de ecdisona/receptor x retinoide de invertebrado.
BR0009393A (pt) Polipeptìdeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, método para a produção do polipeptìdeo, uso de um polipeptìdeo, e, composição detergente
AR014891A1 (es) Genes aislados de proteinas de membranas de mamiferos; reactivos relacionados
IL191995A0 (en) Hybrid 3' untranslated regions suitable for efficient protein expression in mammalian cells
DK1176205T3 (da) Ekspression af alkalisk phosphatase i gær
DK0804558T3 (da) Tripeptidylaminopeptidase
BR9811865A (pt) Isolamento de um novo gene de fator de senescência, p23
DE69504808D1 (de) Corticotropin freisetzende rezeptoren des faktor 2
TR200000288T2 (tr) İnsülin C-peptidin rekombinan ekspresyonu.
ATE546531T1 (de) Transaktivierungssystem für säugerzellen
ATE443158T1 (de) Vektorvermittelte organellentransfektion
DK0811071T3 (da) Amplifikeringssekvenser hidrørende fra desmin-genet, vektorer indeholdende disse sekvenser og anvendelse heraf til fremstilling af proteiner
ATE288488T1 (de) Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
ES2136284T3 (es) Adn que codifica el precursor de la proteinasa iii de cisteina relacionada con la enzima convertidora de interleucina 1-beta (icerel-iii).
ATE455856T1 (de) Hitzeinduzierbarer promotor
ATE297999T1 (de) Dna expression in transfizierten zellen und testverfahren in transfiziereen zellen
DE602004027077D1 (de) Genschalter-kontrollierte virale vektoren
ES2136285T3 (es) Adn que codifica el precursor de la proteinasa ii de cisteina relacionada con la enzima convertidora de interleucina 1-beta (icerel-ii).
DE69637684D1 (de) Dna moleküle

Legal Events

Date Code Title Description
8364 No opposition during term of opposition